

# Recombinant human epidermal growth factor (REGEN-D 150): effect on healing of diabetic foot ulcers. - PubMed

Author information

## Abstract

Recombinant human epidermal growth factor (REGEN-D 150), which was cloned and over expressed in *E. coli*, has shown enhanced healing of chronic diabetic foot ulcers (DFU) by significantly reducing the duration of healing in addition to providing excellent quality of wound healing and reepithelization. Post-marketing surveillance (PMS) study of REGEN-D 150 in 135 patients of DFU in India was compared with Phase III clinical trial data of REGEN-D 150 in India. Statistical analysis of study data determined that the empirical survival probability distribution, in terms of non-healing of ulcers, was lowest in the case of PMS study, better than that for Phase III; more DFU patients were healed in PMS study. Percentage of patients cured in any given week (e.g., in week 10) is above 90% in PMS study, as compared to 69% in Phase III clinical trial; this percentage was around 18% for the control group with placebo in the Phase III trial. The average wound healing time was significantly lower in PMS study, 4.8 weeks, while it was 9 weeks in Phase III clinical trials while the average wound healing with REGEN-D 150 was found to be 86% in this study. REGEN-D 150 has been found to result in healthy granulation and stimulate epithelization, thus leading to final wound closure. The PMS study has established the efficacy of REGEN-D 150 in faster healing of diabetic foot ulcers.

PMID:

17655964

DOI:

[10.1016/j.diabres.2007.06.004](https://doi.org/10.1016/j.diabres.2007.06.004)

[Indexed for MEDLINE]

- [Share on Facebook](#)
- [Share on Twitter](#)
- [Share on Google+](#)
- [Diabetes Care. 2003]
- [Int Wound J. 2007]
- [Int Wound J. 2009]